What happened
The Trump administration has reached agreements with 26 pharmaceutical companies to offer Medicaid the same low prices that foreign countries pay, in exchange for sparing these manufacturers from tariffs. This effort is part of a broader strategy to combat foreign free-riding, where other wealthy nations impose price controls on medicines invented in American labs, forcing Americans to foot the bill for research and development.
The administration has also struck a deal with the U.K., which agreed to double its spending on new drugs as a share of GDP in exchange for an exemption from certain tariffs. Similar investigations and negotiations are underway with other countries, including Germany and Japan, to compel them to adopt meaningful reforms and pay American-level prices for cutting-edge medicines.
Additionally, the administration is taking on pharmacy benefit managers and large insurance conglomerates that unfairly raise consumers' drug costs, with the Federal Trade Commission securing landmark settlements to increase transparency and stop artificially inflating prices for patients.
